Company intelligence / Profile preview

ATI Inc.

Ownership: Public · ATI
Development stage: Other

Overview

Enables biotechnology/pharmaceutical R&D through advanced software technologies including laboratory automation systems (high throughput genomics/proteomics), bioinformatics tools for sequencing/comparative genomics/pathogen analysis; develops microfluidic chips supporting cancer cell/tissue culture analysis for personalized medicine applications; offers web-based clinical trial data capture/infrastructure services to pharma sponsors across all phases of development. Does NOT develop its own therapeutics/pipeline programs.

Industry: Drug Discovery Services

Partnerships

Academic institutionsCommercial partners

Financials

Market cap: $28.3B
Total revenue: $1.3B
Enterprise value: $29.7B

Beyond the preview

Go deeper on ATI Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATI Inc..

Explore the full profile